Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
Multicenter Study Clinical Trial
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good tolerability in non-small cell lung cancer (NSCLC). In particular, higher response rates have been reported in Asian patients than in Western patients. The aim of this study conducted by the Korean Cancer Study Group was to evaluate the efficacy and tolerability of erlotinib monotherapy as a palliative treatment for advanced NSCLC patients in Korea. ⋯ Erlotinib monotherapy showed significant antitumor activity and an acceptable tolerability profile as a palliative treatment in advanced NSCLC patients in Korea, especially in females, never smokers, and patients with adenocarcinoma histology.
-
Detection of nonsmall cell lung cancer at the intraepithelial stage is believed to improve cure rates. New bronchoscopic technologies, including white light videobronchoscopy (WLB), autofluorescence imaging (AFI), and narrow band imaging (NBI), are aiming to diagnose airway neoplasia at a preinvasive stage. ⋯ NBI is an alternative to AFI in the detection of early lung cancers because it has a comparatively higher specificity without significantly compromising the sensitivity.